No Data
No Data
Dezhan Health: 2024 Semi-Annual Report Summary
Dezhan Health: Semi-Annual Report 2024
dezhan healthcare (000813.SZ) released its performance for the first half of the year, with a net income of 10.1526 million yuan, turning losses into profits year on year.
Dezhan Healthcare (000813.SZ) released its semi-annual report for 2024, during which the company achieved revenue of 2...
Dezhan Healthcare (000813.SZ): The net income in the first half of the year was 10.1526 million yuan, a year-on-year recovery from losses.
Gelonghui, August 27th, Dezhan Healthcare (000813.SZ) announced its 2024 interim report, with a revenue of 0.248 billion yuan during the reporting period, a 12.46% year-on-year growth; the net income attributable to the shareholders of the listed company was 10.1526 million yuan, turning losses into profits year-on-year; the net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 7.9021 million yuan; the basic earnings per share was 0.0047 yuan.
Dezhan Healthcare (000813.SZ): Eastern Strategy ABC-3100 is the world's first HPV therapeutic vaccine developed based on DNA technology.
Dezhan Healthcare (000813.SZ) stated on the investor interaction platform on August 21 that Eaststrait ABC-3100 (also known as VGX-3100) is the world's first HPV therapeutic vaccine developed based on DNA technology platform.
Express News | Dezhan Healthcare: applies for compulsory enforcement of 471 million yuan.
No Data